Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria
D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series
D1.376 - Emerging inmunomodulatory agents for atopic dermatitis
D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report
D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis
D1.379 - AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)
D1.380 - Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow
D1.383 - Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report
D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis
D1.385 - Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity
D1.386 - Impact of dupilumab on allergen specific immunoglobulin E production
D1.44 - A Difficult to Treat Chronic Urticaria With Psychological Stress, High Anti-Thyroglobulin and De-labeling Hypersensitivity Reaction to Cetirizine
D1.45 - Omalizumab Reduces Anaphylactic Reactions and Facilitates Food Introduction in Food-Allergic Children with Severe Asthma: A Case Report
D1.48 - Challenging decisions: Feasibility and safety of multiple low-risk drug challenges in a single clinic visit during peri-operative anaphylaxis investigation
D1.49 - Crossed-reactivity among Proton Pump Inhibitors in Immediate Severe Hipersensitivity Reactions
D1.50 - Coconut Oil Anaphylaxis after Mucous Exposure, in a Patient with Primary Coconut Allergy
D1.53 - Anaphylaxis to Beta-Lactams: The Importance of the Oral Challenge Test in Diagnosis
D1.54 - Nut Allergy in the Spotlight: The Crucial Role of Oral Provocation Tests
D1.55 - Assembling the Idiopathic Anaphylaxis Puzzle: Where was the secret key for Idiopathic anaphylaxis’s box?
D1.46 - Allergic Reaction to Quadrivalent Meningococcal Conjugate Vaccine (MCV4): Case Report and Diagnostic Approach
Download the app
The congress at your fingertips
Available on
Download